Imatinib (CAS NO.152459-95-5) was developed by rational drug design. After the Philadelphia chromosome mutation and defective bcr-abl protein were discovered, the investigators screened chemical libraries to find a drug that would inhibit that protein. They identified 2-phenylaminopyrimidine with high-throughput screening, then it is tested and modified by the introduction of methyl and benzamide groups to give it enhanced binding properties, producing Imatinib.

1. Introduction of Imatinib
Imatinib is one kind of white to off-white crystalline or pale yellow powder. The IUPAC Name of this chemical is 4-[(4-Methylpiperazin-1-yl)methyl]-N-[4-methyl-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]phenyl]benzamide. Besides, Imatinib belongs to Molecular Targeted Antineoplastic;Pharmaceutical intermediate;Imatinib. In addition, the Classification Code of this chemical is Antineoplastic; Antineoplastic Agents; Enzyme Inhibitors; Protein Kinase Inhibitors. Imatinib is very soluble in water at pH < 5.5 (mesylate salt). It should be stored at refrigerator.

2. Properties of Imatinib
Physical properties about Imatinib are:
(1)Index of Refraction:  1.671; (2)Surface Tension:  63.6 dyne/cm; (3)Density:  1.255 g/cm³; (4)H bond acceptors:  8; (5)H bond donors:  2; (6)Freely Rotating Bonds:  6; (7)Polar Surface Area:  68.7 Å²; (8)Index of Refraction:  1.671; (9)Molar Refractivity:  147.09 cm³; (10)Molar Volume:  393 cm³; (11)XLogP3-AA: 3.5; (12)H-Bond Donor: 2; (13)H-Bond Acceptor: 7; (14)Rotatable Bond Count: 7; (15)Tautomer Count: 6; (16)Exact Mass: 493.259009; (17)MonoIsotopic Mass: 493.259009; (18)Topological Polar Surface Area: 86.3; (19)Heavy Atom Count: 37; (20)Formal Charge: 0; (21)Complexity: 706; (22)Isotope Atom Count: 0; (23)Defined Atom Stereocenter Count: 0; (24)Undefined Atom Stereocenter Count: 0; (25)Defined Bond Stereocenter Count: 0; (26)Undefined Bond Stereocenter Count: 0; (27)Covalently-Bonded Unit Count: 1; (28)Feature 3D Acceptor Count: 3; (29)Feature 3D Donor Count: 2; (30)Feature 3D Cation Count: 3; (31)Feature 3D Ring Count: 5; (32)Effective Rotor Count: 9.2; (33)Conformer Sampling RMSD: 1.

3. Structure Descriptors of Imatinib
(1)SMILES: O=C(Nc3ccc(c(Nc2nc(c1cccnc1)ccn2)c3)C)c4ccc(cc4)CN5CCN(CC5)C
InChI: InChI=1/C29H31N7O/c1-21-5-10-25(18-27(21)34-29-31-13-11-26(33-29)24-4-3-12-30-19-24)32-28(37)23-8-6-22(7-9-23)20-36-16-14-35(2)15-17-36/h3-13,18-19H,14-17,20H2,1-2H3,(H,32,37)(H,31,33,34)
(2)InChIKey: KTUFNOKKBVMGRW-UHFFFAOYAJ
(3)Std. InChI: InChI=1S/C29H31N7O/c1-21-5-10-25(18-27(21)34-29-31-13-11-26(33-29)24-4-3-12-30-19-24)32-28(37)23-8-6-22(7-9-23)20-36-16-14-35(2)15-17-36/h3-13,18-19H,14-17,20H2,1-2H3,(H,32,37)(H,31,33,34)
(4)Std. InChIKey: KTUFNOKKBVMGRW-UHFFFAOYSA-N

4. Uses of Imatinib
Imatinib is used in chronic myelogenous leukemia (CML), gastrointestinal stromal tumors (GISTs) and a number of other malignancies. Imatinib (originally STI571) is a drug used to treat certain cancers. It is the first member of a new class of agents that act by inhibiting particular tyrosine kinase enzymes, instead of non-specifically inhibiting rapidly dividing cells.

5. Production of Imatinib
N-(5-Amino-2-methylphenyl)-4-(3-pyridyl)-2-pyrimidineamine and 4-(4-Methylpiperazin-1-ylmethyl)benzoyl chloride can used to manufacture Imatinib when them are soluble in Azabenzene. And the condition of this reaction can be taken place under the room temperature and nitrogen. Then stir them, reduced pressure concentration, add water, cooling, filter, filter cake vacuum drying, join methylene chloride - methanol, and filtering. At last, you can get the Imatinib.